TEM vs VCYT
TEM: Tempus AI leverages a massive library of multimodal clinical and molecular data to power AI-driven precision medicine for patients and researchers. VCYT: Veracyte is a genomic diagnostics company transforming cancer care with advanced, high-value testing platforms across the patient journey from diagnosis to monitoring.
Side-by-side fundamentals
| Metric | TEM | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $69.28 | $43.60 | |
| Market cap | $9.8B | $3.5B | |
| P/E as of 2026-10-08 | n/a | 31.08 | |
| Net margin FY2025, SEC XBRL | -19.3% | +12.8% | VCYT higher |
| Gross margin FY2025, SEC XBRL | n/a | +70.1% | |
| Operating margin FY2025, SEC XBRL | -19.9% | +11.2% | VCYT higher |
| ROE FY2025, SEC XBRL | -49.9% | +5.1% | VCYT higher |
| ROA FY2025, SEC XBRL | -10.8% | +4.7% | VCYT higher |
| Debt / equity as of 2026-09-02 | 3.06 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-09-02 | +50.4% | +17.3% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +58.3% | +20.4% | TEM higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 2.69 | 1.32 | |
| 1-year return as of 2026-10-08 close | -32.9% | +24.2% | VCYT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.